ProPhase Labs, Inc. (NASDAQ:PRPH - Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.77 and traded as high as $6.55. ProPhase Labs shares last traded at $6.47, with a volume of 16,000 shares traded.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and set a $11.00 price objective on shares of ProPhase Labs in a research report on Wednesday, February 21st.
Read Our Latest Analysis on PRPH
ProPhase Labs Stock Performance
The stock has a market capitalization of $116.75 million, a P/E ratio of -11.76 and a beta of -0.34. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.73 and a current ratio of 3.04. The business's fifty day moving average price is $5.12 and its two-hundred day moving average price is $4.78.
Institutional Trading of ProPhase Labs
A number of hedge funds and other institutional investors have recently bought and sold shares of PRPH. Tower Research Capital LLC TRC purchased a new position in ProPhase Labs during the 2nd quarter valued at about $42,000. Royal Bank of Canada raised its position in ProPhase Labs by 2,166.7% during the 2nd quarter. Royal Bank of Canada now owns 10,880 shares of the company's stock worth $79,000 after buying an additional 10,400 shares during the last quarter. Jane Street Group LLC acquired a new stake in ProPhase Labs during the 4th quarter worth about $118,000. Goldman Sachs Group Inc. acquired a new stake in ProPhase Labs during the second quarter worth about $164,000. Finally, Morgan Stanley lifted its stake in shares of ProPhase Labs by 50.8% in the 4th quarter. Morgan Stanley now owns 14,683 shares of the company's stock valued at $141,000 after purchasing an additional 4,945 shares during the period. Hedge funds and other institutional investors own 9.45% of the company's stock.
About ProPhase Labs
(
Get Free Report)
ProPhase Labs, Inc engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Recommended Stories
Before you consider ProPhase Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProPhase Labs wasn't on the list.
While ProPhase Labs currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
